Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors

NCT02923349 is registered in ClinicalTrials.gov with Incyte Biosciences International Sàrl as lead sponsor.

NCT NCT02923349
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02923349 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors
Lead sponsor
Incyte Biosciences International Sàrl
Phase
Phase 1/2
Overall status
Completed
Start date
October 31, 2016
Completion date
March 26, 2019
Enrollment
87 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignancies, metastatic cancer